2,855
edits
mNo edit summary |
mNo edit summary |
||
Line 83: | Line 83: | ||
</ref>. | </ref>. | ||
Emotions and brain function are altered up to one month after a single high dose of psilocybin<ref>'''Emotions and brain function are altered up to one month after a single high dose of psilocybin.''' Barrett, F.S., Doss, M.K., Sepeda, N.D. ''et al.'' ''Sci Rep'' 10, 2214 (2020). <nowiki>https://doi.org/10.1038/s41598-020-59282-y</nowiki></ref>. Psychedelic use correlates to lifetimes without [[depression]]<ref>'''Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.''' Grant M Jones., Matthew K Nock. Published January 5, 2022 in Volume 36, Issue 1 of Journal of Psychopharmacology. https://doi.org/10.1177/026988112</ref>. Numerous studies<ref>'''Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.''' Eduardo Ekman Schenberg. Front Pharmacol. 2018; 9: 733. Published online 2018 Jul 5. doi: 10.3389/fphar.2018.00733.</ref> and a systematic review<ref>'''A systematic review of psychedelic-assisted psychotherapy for mental health''': An evaluation of the current wave of research and suggestions for the future. Wheeler, S. W., & Dyer, N. L. (2020). Psychology of Consciousness: Theory, Research, and Practice, 7(3), 279–315. <nowiki>https://doi.org/10.1037/cns0000237</nowiki></ref> have concluded that [[Guided Psychedelic Therapy|guided psychedelic therapy]] can further improve the above therapeutic effects. | Emotions and brain function are altered up to one month after a single high dose of psilocybin<ref>'''Emotions and brain function are altered up to one month after a single high dose of psilocybin.''' Barrett, F.S., Doss, M.K., Sepeda, N.D. ''et al.'' ''Sci Rep'' 10, 2214 (2020). <nowiki>https://doi.org/10.1038/s41598-020-59282-y</nowiki></ref>. Psychedelic use correlates to lifetimes without [[depression]]<ref>'''Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.''' Grant M Jones., Matthew K Nock. Published January 5, 2022 in Volume 36, Issue 1 of Journal of Psychopharmacology. https://doi.org/10.1177/026988112</ref>. Numerous studies<ref>'''Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.''' Eduardo Ekman Schenberg. Front Pharmacol. 2018; 9: 733. Published online 2018 Jul 5. doi: 10.3389/fphar.2018.00733.</ref> and a systematic review<ref>'''A systematic review of psychedelic-assisted psychotherapy for mental health''': An evaluation of the current wave of research and suggestions for the future. Wheeler, S. W., & Dyer, N. L. (2020). Psychology of Consciousness: Theory, Research, and Practice, 7(3), 279–315. <nowiki>https://doi.org/10.1037/cns0000237</nowiki></ref> have concluded that [[Guided Psychedelic Therapy|guided psychedelic therapy]] can further improve the above therapeutic effects. | ||
=== Learning Enhancement === | |||
New evidence<ref>'''Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans.''' Psychological Medicine, 1-12. doi:10.1017/S0033291722002963, Kanen, J., Luo, Q., Rostami Kandroodi, M., Cardinal, R., Robbins, T., Nutt, D., . . . Den Ouden, H. (2022). Accessed on 24 August 2023 via <nowiki>https://www.cambridge.org/core/journals/psychological-medicine/article/effect-of-lysergic-acid-diethylamide-lsd-on-reinforcement-learning-in-humans/28E41FEE97D3A8614C77DC54DF501489</nowiki></ref> suggests that psychedelics can enhance a specific type of learning called the [[Reward Learning Rate|reward learning rate]] which is how quickly an someone updates their knowledge or policy based on the rewards they receive from the environment. | |||
== Mechanism of Action == | == Mechanism of Action == |